A Study of Olverembatinib in SDH-deficient GIST.

Summary

An international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously been treated with one-line therapy, and to evaluate the progression-free survival and clinical benefit rate of olverembatinib in patients with SDH-deficient GIST.

Timeline

Start

2024-11-11

Primary completion

2027-03-31

Completion

2029-06-30

Drugs

Indications